These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19335936)

  • 1. The acute effects of synthetic intravenous Delta9-tetrahydrocannabinol on psychosis, mood and cognitive functioning.
    Morrison PD; Zois V; McKeown DA; Lee TD; Holt DW; Powell JF; Kapur S; Murray RM
    Psychol Med; 2009 Oct; 39(10):1607-16. PubMed ID: 19335936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation.
    Morrison PD; Stone JM
    Hum Psychopharmacol; 2011 Jan; 26(1):77-80. PubMed ID: 23055415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis.
    Bhattacharyya S; Fusar-Poli P; Borgwardt S; Martin-Santos R; Nosarti C; O'Carroll C; Allen P; Seal ML; Fletcher PC; Crippa JA; Giampietro V; Mechelli A; Atakan Z; McGuire P
    Arch Gen Psychiatry; 2009 Apr; 66(4):442-51. PubMed ID: 19349314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic moderation of the effects of cannabis: catechol-O-methyltransferase (COMT) affects the impact of Δ9-tetrahydrocannabinol (THC) on working memory performance but not on the occurrence of psychotic experiences.
    Tunbridge EM; Dunn G; Murray RM; Evans N; Lister R; Stumpenhorst K; Harrison PJ; Morrison PD; Freeman D
    J Psychopharmacol; 2015 Nov; 29(11):1146-51. PubMed ID: 26464454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis.
    D'Souza DC; Perry E; MacDougall L; Ammerman Y; Cooper T; Wu YT; Braley G; Gueorguieva R; Krystal JH
    Neuropsychopharmacology; 2004 Aug; 29(8):1558-72. PubMed ID: 15173844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing.
    Fusar-Poli P; Crippa JA; Bhattacharyya S; Borgwardt SJ; Allen P; Martin-Santos R; Seal M; Surguladze SA; O'Carrol C; Atakan Z; Zuardi AW; McGuire PK
    Arch Gen Psychiatry; 2009 Jan; 66(1):95-105. PubMed ID: 19124693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of acute effects of delta-9-tetrahydrocannabinol on psychotomimetic effects, cognition and brain function by previous cannabis exposure.
    Colizzi M; McGuire P; Giampietro V; Williams S; Brammer M; Bhattacharyya S
    Eur Neuropsychopharmacol; 2018 Jul; 28(7):850-862. PubMed ID: 29935939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction.
    D'Souza DC; Abi-Saab WM; Madonick S; Forselius-Bielen K; Doersch A; Braley G; Gueorguieva R; Cooper TB; Krystal JH
    Biol Psychiatry; 2005 Mar; 57(6):594-608. PubMed ID: 15780846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Δ9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers.
    Atakan Z; Bhattacharyya S; Allen P; Martín-Santos R; Crippa JA; Borgwardt SJ; Fusar-Poli P; Seal M; Sallis H; Stahl D; Zuardi AW; Rubia K; McGuire P
    Psychol Med; 2013 Jun; 43(6):1255-67. PubMed ID: 23020923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
    Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
    Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosis-Relevant Effects of Intravenous Delta-9-Tetrahydrocannabinol: A Mega Analysis of Individual Participant-Data from Human Laboratory Studies.
    Ganesh S; Cortes-Briones J; Ranganathan M; Radhakrishnan R; Skosnik PD; D'Souza DC
    Int J Neuropsychopharmacol; 2020 Dec; 23(9):559-570. PubMed ID: 32385508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial.
    Englund A; Atakan Z; Kralj A; Tunstall N; Murray R; Morrison P
    J Psychopharmacol; 2016 Feb; 30(2):140-51. PubMed ID: 26577065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness.
    Koethe D; Gerth CW; Neatby MA; Haensel A; Thies M; Schneider U; Emrich HM; Klosterkötter J; Schultze-Lutter F; Leweke FM
    Schizophr Res; 2006 Dec; 88(1-3):142-50. PubMed ID: 17005373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute and residual mood and cognitive performance of young adults following smoked cannabis.
    Matheson J; Mann RE; Sproule B; Huestis MA; Wickens CM; Stoduto G; George TP; Rehm J; Le Foll B; Brands B
    Pharmacol Biochem Behav; 2020 Jul; 194():172937. PubMed ID: 32360692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Central nervous system effects of haloperidol on THC in healthy male volunteers.
    Liem-Moolenaar M; te Beek ET; de Kam ML; Franson KL; Kahn RS; Hijman R; Touw D; van Gerven JM
    J Psychopharmacol; 2010 Nov; 24(11):1697-708. PubMed ID: 20142302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms.
    Morrison PD; Nottage J; Stone JM; Bhattacharyya S; Tunstall N; Brenneisen R; Holt D; Wilson D; Sumich A; McGuire P; Murray RM; Kapur S; Ffytche DH
    Neuropsychopharmacology; 2011 Mar; 36(4):827-36. PubMed ID: 21150914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased hippocampal engagement during learning as a marker of sensitivity to psychotomimetic effects of δ-9-THC.
    Bhattacharyya S; Sainsbury T; Allen P; Nosarti C; Atakan Z; Giampietro V; Brammer M; McGuire PK
    Psychol Med; 2018 Dec; 48(16):2748-2756. PubMed ID: 29502548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Previous cannabis exposure modulates the acute effects of delta-9-tetrahydrocannabinol on attentional salience and fear processing.
    Colizzi M; McGuire P; Giampietro V; Williams S; Brammer M; Bhattacharyya S
    Exp Clin Psychopharmacol; 2018 Dec; 26(6):582-598. PubMed ID: 30138003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.
    Cortes-Briones JA; Cahill JD; Skosnik PD; Mathalon DH; Williams A; Sewell RA; Roach BJ; Ford JM; Ranganathan M; D'Souza DC
    Biol Psychiatry; 2015 Dec; 78(11):805-13. PubMed ID: 25913109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood.
    Manning B; Hayley AC; Catchlove S; Stough C; Downey LA
    Eur Neuropsychopharmacol; 2024 May; 82():35-43. PubMed ID: 38490083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.